A review on “monoclonal antibodies: effective treatment against COVID-19”


  • Meghana M. Dabhadkar Department of pharmaceutics, Indira College of Pharmacy, Tathawade, Pune, Maharashtra, India
  • Samiksha Rohidas Palekar Department of pharmaceutics, Indira College of Pharmacy, Tathawade, Pune, Maharashtra, India
  • Kaustubh Navnath Pawar Department of pharmaceutics, Indira College of Pharmacy, Tathawade, Pune, Maharashtra, India




Coronavirus, Outbreak, Pandemic, Diagnostic tests, Medication, Monoclonal antibodies


Novel coronavirus disease caused by the SARS-CoV-19 virus enters the host cell through the S-spike protein by binding to ACE-2. In December 2019, an outbreak of coronavirus originated from Wuhan, China and by the end of 2020, it was recorded in almost every part of the world including Italy, Germany, Iran, Spain, and also United states. This led to a Pandemic which was declared by World Health Organization on 11th March 2020. SARS-CoV-19 causes mild to moderate illness which leads to acute respiratory syndrome, by causing infection in the nose, sinuses, or upper throat. It can also affect the upper or lower respiratory tract and has caused millions of cases and deaths. Many diagnostic tests have been authorized by the WHO including Direct and Indirect tests. Due to the increase in the number of covid 19 cases, many medications were introduced as per the demands like anti-malarial drugs, anti-viral drugs, antibiotics, anti-inflammatory drugs, steroids, biological agents, etc. The SARS-CoV-2 has a spike protein on its surface that aids in the virus's attachment to and entry into human cells. To attach to the protein of SARS-spike-CoV-2 and stop the virus from infecting human cells, many monoclonal antibodies like Casirivimab, imdevimab, Tocilizumab, Sarilumab, Itolizumab, Siltuximab have been created. As monoclonal antibodies prevent viruses from entering cells and continuing to proliferate, as well as lowering viral loads and lowering the frequency of hospital visits, they can be used as an alternative to conventional therapies. Hence monoclonal antibody treatment can be considered an effective alternative treatment for treating SARS-CoV-2.


Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37:100738.

Jiang MD, Zu ZY, Schoepf UJ, Savage RH, Zhang XL, Lu GM, et al. Current Status of Etiology, Epidemiology, Clinical Manifestations and Imagings for COVID-19. Korean J Radiol. 2020;21(10):1138.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100–17.

Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020;11(4):245–68.

WHO Coronavirus (COVID-19) Dashboard [Internet]. Available from: https://covid19.who.int. Last accessed 3 October 2022.

Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Trends Pharmacol Sci. 2020;41(11):815–29.

Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al. COVID-19 Outbreak: An Overview. Chemotherapy. 2019;64(5–6):215–23.

Yamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, et al. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. J Alzheimers Dis. 2020;77(2):459–504.

Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.

Jin P, Park H, Jung S, Kim J. Challenges in Urology during the COVID-19 Pandemic. Urol Int. 2021;105(1–2):3–16.

Ciotti M, Benedetti F, Zella D, Angeletti S, Ciccozzi M, Bernardini S. SARS-CoV-2 Infection and the COVID-19 Pandemic Emergency: The Importance of Diagnostic Methods. Chemotherapy. 2021;66(1–2):17–23.

Grau-López L, Daigre C, Palma-Alvarez RF, Sorribes-Puertas M, Serrano-Pérez P, Quesada-Franco M, et al. COVID-19 Lockdown and Consumption Patterns among Substance Use Disorder Outpatients: A Multicentre Study. Eur Addict Res. 2022;28(4):243–54.

Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatr Respir Rev. 2021;39:22–31.

La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online. 2020;41(3):483–99.

Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis —A review of current methods. Biosens Bioelectron. 2021;172:112752.

Chen PL, Lee NY, Cia CT, Ko WC, Hsueh PR. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. Front Pharmacol. 2020;11:584956.

Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372.

Rauf A, Abu-Izneid T, Olatunde A, Ahmed Khalil A, Alhumaydhi FA, Tufail T, et al. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health. 2020;17(21):8155.

Syal K. COVID‐19: Herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020;92(9):1380–2.

Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(17):4593–5.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–6.

Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges, and future prospects. Hum Cell. 2021;34(3):711–33.

Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for the treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–93.

Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015.

Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol [Internet]. 2020 [cited 2022 Jul 22]; Available from: http://apjai-journal.org/wp-content/uploads/2020/03/2.pdf.

Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 2020;129:110337.

Marovich M, Mascola JR, Cohen MS. Monoclonal Antibodies for Prevention and Treatment of COVID-19. JAMA. 2020;324(2):131.

Janeway C, editor. Immunobiology: the immune system in health and disease ; [animated CD-ROM inside]. 5. ed. New York, NY: Garland Publ. [u.a.]; 2001. 732 p.

Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 2021;9(6):557.

Lu W, Wu P, He L, Meng Y, Wu P, Ding W, et al. Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study. Infect Dis Ther. 2021;10(3):1379–90.

Tuladhar R. Implication of Monoclonal Antibody for COVID-19 Treatment. J Inst Sci Technol. 2020;25(2):133–40.

Deb P, Molla MdMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87–91.

Saavedra D, Añé-Kourí AL, Sánchez N, Filgueira LM, Betancourt J, Herrera C, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020;17(1):34.

Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2021;384(3):229–37.

Allam A, Lippmann S. Sotrovimab: Neutralizing Antibody to Combat COVID-19. Univ Louisville J Respir Infect [Internet]. 2022 Apr 20 [cited 2022 Oct 2];6(1). Available from: https://ir.library.louisville.edu/jri/vol6/iss1/9.

Cohen MS. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection. N Engl J Med. 2021;384(3):289–91.

Mahase E. Covid-19: UK approves first monoclonal antibody treatment. BMJ. 2021;n20:83.

Rubin E, Dryden-Peterson SL, Hammond SP, Lennes I, Letourneau AR, Pathak P, et al. A Novel Approach to Equitable Distribution of Scarce Therapeutics. Chest. 2021;160(6):2324–31.

Mornese Pinna S, Lupia T, Scabini S, Vita D, De Benedetto I, Gaviraghi A, et al. Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm? Int Immunopharmacol. 2021;101:108200.

Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331.

Medina Gamero A, Regalado Chamorro M. Monoclonal antibodies as a treatment for COVID-19. Neurol Perspect. 2022;2(1):47–8.




How to Cite

Dabhadkar, M. M., Palekar, S. R., & Pawar, K. N. (2022). A review on “monoclonal antibodies: effective treatment against COVID-19”. International Journal Of Community Medicine And Public Health, 10(1), 525–534. https://doi.org/10.18203/2394-6040.ijcmph20223584



Review Articles